Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy
Key clinical message Nivolumab has been clinically successful in prolonging the overall survival of patients with recurrent and metastatic head and neck cancer, complete remission is rare. Synergistic combinations of immunotherapy and conventional cancer treatments, such as radiotherapy or chemother...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.8219 |
| _version_ | 1827395311983656960 |
|---|---|
| author | Katsuhisa Sekido Shuichi Imaue Hidetake Tachinami Kei Tomihara Norihito Naruto Kentaro Yamagishi Atsushi Ikeda Kumiko Fujiwara Makoto Noguchi |
| author_facet | Katsuhisa Sekido Shuichi Imaue Hidetake Tachinami Kei Tomihara Norihito Naruto Kentaro Yamagishi Atsushi Ikeda Kumiko Fujiwara Makoto Noguchi |
| author_sort | Katsuhisa Sekido |
| collection | DOAJ |
| description | Key clinical message Nivolumab has been clinically successful in prolonging the overall survival of patients with recurrent and metastatic head and neck cancer, complete remission is rare. Synergistic combinations of immunotherapy and conventional cancer treatments, such as radiotherapy or chemotherapy, are likely to be the most viable strategies for improving patient responses. Abstract Immune checkpoint inhibitors have revolutionized recurrent, metastatic oral cancer treatment; however complete remission in advanced stages is unusual. We present a case of complete remission of advanced oral squamous cell carcinoma for >4 years in a 64‐year‐old Japanese woman, that responded poorly to chemoradiotherapy but well to subsequent nivolumab treatment. |
| first_indexed | 2024-03-08T18:30:26Z |
| format | Article |
| id | doaj.art-21f1719b057748638c81ca0cf8df9265 |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-03-08T18:30:26Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-21f1719b057748638c81ca0cf8df92652023-12-30T04:35:08ZengWileyClinical Case Reports2050-09042023-12-011112n/an/a10.1002/ccr3.8219Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapyKatsuhisa Sekido0Shuichi Imaue1Hidetake Tachinami2Kei Tomihara3Norihito Naruto4Kentaro Yamagishi5Atsushi Ikeda6Kumiko Fujiwara7Makoto Noguchi8Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Academic Assembly University of Toyama 2630 Sugitani Toyama City JapanDepartment of Oral and Maxillofacial Surgery, Faculty of Medicine, Academic Assembly University of Toyama 2630 Sugitani Toyama City JapanDepartment of Oral and Maxillofacial Surgery, Faculty of Medicine, Academic Assembly University of Toyama 2630 Sugitani Toyama City JapanDivisions of Oral and Maxillofacial Surgery Niigata University Graduate School of Medical and Dental Sciences Niigata JapanDepartment of Radiology, Faculty of Medicine, Academic Assembly University of Toyama Toyama City JapanDepartment of Radiology, Faculty of Medicine, Academic Assembly University of Toyama Toyama City JapanDepartment of Oral and Maxillofacial Surgery, Faculty of Medicine, Academic Assembly University of Toyama 2630 Sugitani Toyama City JapanDepartment of Dentistry and Oral Surgery, Division of Medicine for Function and Morphology of Sensory Organs, Faculty of Medicine Osaka Medical and Pharmaceutical University Takatsuki JapanDepartment of Oral and Maxillofacial Surgery, Faculty of Medicine, Academic Assembly University of Toyama 2630 Sugitani Toyama City JapanKey clinical message Nivolumab has been clinically successful in prolonging the overall survival of patients with recurrent and metastatic head and neck cancer, complete remission is rare. Synergistic combinations of immunotherapy and conventional cancer treatments, such as radiotherapy or chemotherapy, are likely to be the most viable strategies for improving patient responses. Abstract Immune checkpoint inhibitors have revolutionized recurrent, metastatic oral cancer treatment; however complete remission in advanced stages is unusual. We present a case of complete remission of advanced oral squamous cell carcinoma for >4 years in a 64‐year‐old Japanese woman, that responded poorly to chemoradiotherapy but well to subsequent nivolumab treatment.https://doi.org/10.1002/ccr3.8219chemoradiotherapycomplete remissionimmune checkpoint inhibitornivolumaboral squamous cell carcinoma |
| spellingShingle | Katsuhisa Sekido Shuichi Imaue Hidetake Tachinami Kei Tomihara Norihito Naruto Kentaro Yamagishi Atsushi Ikeda Kumiko Fujiwara Makoto Noguchi Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy Clinical Case Reports chemoradiotherapy complete remission immune checkpoint inhibitor nivolumab oral squamous cell carcinoma |
| title | Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy |
| title_full | Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy |
| title_fullStr | Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy |
| title_full_unstemmed | Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy |
| title_short | Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy |
| title_sort | successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy |
| topic | chemoradiotherapy complete remission immune checkpoint inhibitor nivolumab oral squamous cell carcinoma |
| url | https://doi.org/10.1002/ccr3.8219 |
| work_keys_str_mv | AT katsuhisasekido successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy AT shuichiimaue successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy AT hidetaketachinami successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy AT keitomihara successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy AT norihitonaruto successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy AT kentaroyamagishi successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy AT atsushiikeda successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy AT kumikofujiwara successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy AT makotonoguchi successfultreatmentwithnivolumabinapatientwithunresectableoralsquamouscellcarcinomafollowingineffectivechemoradiotherapy |